MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 2, Pages 742-754
Publisher
American Society for Clinical Investigation
Online
2014-01-08
DOI
10.1172/jci70198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis
- (2012) Yilin Huo et al. BIOCHEMICAL JOURNAL
- Translation Regulation as a Therapeutic Target in Cancer: Figure 1.
- (2012) Michal Grzmil et al. CANCER RESEARCH
- MNK1 kinase activity is required for abscission
- (2012) Yoann Rannou et al. JOURNAL OF CELL SCIENCE
- A unifying model for mTORC1-mediated regulation of mRNA translation
- (2012) Carson C. Thoreen et al. NATURE
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway
- (2012) L Adesso et al. ONCOGENE
- MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition
- (2012) A Astanehe et al. ONCOGENE
- MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells
- (2012) Y Shi et al. ONCOGENE
- MAP Kinase-Interacting Kinase 1 Regulates SMAD2-Dependent TGF- Signaling Pathway in Human Glioblastoma
- (2011) M. Grzmil et al. CANCER RESEARCH
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
- (2011) Michal Marzec et al. PLoS One
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues
- (2010) Songqing Fan et al. CANCER BIOLOGY & THERAPY
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- mTOR signaling in glioblastoma: lessons learned from bench to bedside
- (2010) D. Akhavan et al. NEURO-ONCOLOGY
- Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo
- (2010) J P Robinson et al. ONCOGENE
- Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development
- (2010) T. Ueda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
- (2010) L. Furic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
- (2009) Nahum Sonenberg et al. CELL
- Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma
- (2009) K. E. O'Reilly et al. CLINICAL CANCER RESEARCH
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
- (2009) Marc Sanson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells
- (2008) Andrea Bianchini et al. CARCINOGENESIS
- The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)
- (2008) Maria Buxade Frontiers in Bioscience-Landmark
- Peters Plus Syndrome Is a New Congenital Disorder of Glycosylation and Involves DefectiveO-Glycosylation of Thrombospondin Type 1 Repeats
- (2008) Daniel Hess et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
- (2008) Arkaitz Carracedo et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now